LCI Lannett Co., Inc.
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Philadelphia, PA.
Company profile
Ticker
LCI
Exchange
Website
CEO
Timothy C. Crew
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
IRS number
230787699
LCI stock data
()
Calendar
7 Nov 19
7 Dec 19
30 Jun 20
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 127.34M | 133.84M | 172.79M | 193.72M | |
| Net income | -12.16M | -7.59M | 10.65M | 12.36M | |
| Diluted EPS | -0.32 | -0.2 | 0.27 | 0.32 | |
| Net profit margin | -9.55% | -5.67% | 6.16% | 6.38% | |
| Operating income | 9.4M | 9.4M | 33.38M | 36.68M | |
| Net change in cash | -39.24M | -64.96M | 41.43M | 13.45M | |
| Cash on hand | 101.01M | 140.25M | 205.21M | 163.77M | |
| Cost of revenue |
| Annual (USD) | Jun 19 | Jun 18 | Jun 17 | Jun 16 | |
|---|---|---|---|---|---|
| Revenue | 655.41M | 684.56M | 633.34M | 542.49M | |
| Net income | -272.11M | 28.69M | -581K | 44.78M | |
| Diluted EPS | -7.2 | 0.75 | -0.02 | 1.2 | |
| Net profit margin | -41.52% | 4.19% | -0.09% | 8.25% | |
| Operating income | -262.32M | 129.7M | 86.45M | 130.76M | |
| Net change in cash | 41.66M | -19.15M | -107.03M | 24.43M | |
| Cash on hand | 140.25M | 98.59M | 117.74M | 224.77M | |
| Cost of revenue |
Financial data from Lannett earnings reports
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abuse, administered, admission, answer, anti, arrangement, arranging, ASP, asserting, AWP, bear, begun, belonging, bill, breadth, bribe, broader, broadly, cap, capped, carcinogen, Cediprof, certifying, challenge, challenged, clinic, concealing, confirmed, conversion, conveyed, counter, County, criminal, CRL, default, defraud, Discovery, economic, effort, employment, encourage, enforcement, estate, Exhibit, expiry, explicitly, fact, falsifying, felony, FFCA, fit, fraudulent, furnishing, glyburide, HIPAA, holder, hosted, House, human, implicit, implicitly, imposition, imprisonment, improper, improperly, inception, increasingly, indefinitely, indenture, induce, influence, institutional, intent, interpreted, judge, kickback, knowingly, lessee, manner, Minnesota, mismanagement, monetary, NDMA, nominal, occurrence, outlined, outpatient, overstated, owed, passed, payor, PDUFA, person, Posaconazole, PPA, premium, presence, pretax, prohibit, prohibited, prosecuted, prosecution, proxy, Ranitidine, real, recall, recalling, reclassified, redeem, redeemed, redemption, referral, reimburse, reimbursed, reimbursement, remitted, repay, representation, rescind, residual, ROU, scrutiny, Secretary, Senate, soliciting, source, spending, statue, statute, stipulation, successfully, summarily, switching, Syrup, trend, trustee, turn, unavailable, unjustly, unlawful, unpaid, unsecured, VA, Veteran, vigorously, vulnerable, WAC, willfully, world, writ
Removed:
accelerating, affirming, air, analyzing, appeal, appealed, appellate, Aralez, argument, assessment, AstraZeneca, Bankruptcy, base, book, breach, broker, capacity, Cardiovascular, carried, Central, Chapter, Chemical, Circuit, classified, commence, complementary, conducted, conflicting, cooperate, cooperating, core, Cosmetic, counterclaimed, curtail, dealer, declaratory, defense, deficiency, deliberate, demonstrating, depict, difficult, dilution, diversified, Docket, draft, duty, environmental, EPA, evidenced, expanded, expertise, expiring, exploring, extension, factual, failing, favorably, finalize, FOIA, formulate, Freedom, Gastrointestinal, gliburide, global, Glycol, Glycolax, higher, hyclate, identification, Impax, improve, inaccurately, incur, indexed, initiation, innovator, Inter, lack, light, liquidated, long, mandate, matter, meaningful, mentioned, misbranded, Morphine, national, nearer, online, operate, operational, opportunity, optimization, Orange, ordinary, OTC, Pain, PEG, pipeline, point, Polyethylene, prejudice, Prevention, prove, Register, rehearing, reject, Rental, representing, requested, resolution, Rx, salesforce, shift, software, Southern, specialty, specifically, spray, standing, statutory, stay, Sulfate, supplement, terminating, therewith, thyroid, timeline, Trademark, trading, transparent, treatment, trial, UK, unit, unrealized, upholding, USPTO, warrant, withdrawing, Wyoming, Zomig
Financial reports
10-Q
2020 Q1
Quarterly report
7 Nov 19
10-K
2019 FY
Annual report
28 Aug 19
10-Q
2019 Q3
Quarterly report
7 May 19
10-Q
2019 Q2
Quarterly report
7 Feb 19
10-Q
2019 Q1
Quarterly report
8 Nov 18
10-K
2018 FY
Annual report
28 Aug 18
10-Q
2018 Q3
Quarterly report
8 May 18
10-Q
2018 Q2
Quarterly report
8 Feb 18
10-Q
2018 Q1
Quarterly report
8 Nov 17
10-K
2017 FY
Annual report
28 Aug 17
Current reports
8-K
Entry into a Material Definitive Agreement
26 Nov 19
8-K
Lannett Announces Fiscal 2020 First-quarter Financial Results
8 Nov 19
8-K
Other Events
31 Oct 19
8-K
Lannett Announces Closing of $86.25 Million of Convertible Senior Notes Due 2026
27 Sep 19
8-K
Lannett Announces Pricing of $75 Million of Convertible Senior Notes Due 2026
25 Sep 19
8-K
INVESTOR PRESENTATION September 2019 © 2019 Lannett Company, Inc. All Rights Reserved. For Discussion Purposes Only
24 Sep 19
8-K
Lannett Announces Offering of $75 Million of Convertible Senior Notes Due 2026
24 Sep 19
8-K
Lannett Announces Fiscal 2019 Fourth-quarter, Full-year Financial Results; Issues Guidance for Fiscal 2020
28 Aug 19
8-K
Entry into a Material Definitive Agreement
27 Aug 19
8-K
Departure of Directors or Certain Officers
1 Aug 19
Registration and prospectus
S-8
Registration of securities for employees
22 Mar 19
S-3ASR
Automatic shelf registration
13 Feb 18
S-3ASR
Automatic shelf registration
12 May 17
S-8
Registration of securities for employees
23 Jan 14
25
Voluntary exchange delisting
12 Dec 13
8-A12B
Registration of securities on exchange
2 Dec 13
424B5
Prospectus supplement for primary offering
4 Oct 13
FWP
Free writing prospectus
4 Oct 13
424B5
Prospectus supplement for primary offering
3 Oct 13
S-3/A
Shelf registration (amended)
19 Nov 12
Proxies
DEF 14A
Definitive proxy
6 Dec 19
DEFA14A
Additional proxy soliciting materials
21 Dec 18
DEF 14A
Definitive proxy
10 Dec 18
DEF 14A
Definitive proxy
7 Dec 17
DEF 14A
Definitive proxy
12 Dec 16
DEF 14A
Definitive proxy
8 Dec 15
PRE 14A
Preliminary proxy
27 Nov 15
DEF 14A
Definitive proxy
16 Dec 14
DEF 14A
Definitive proxy
17 Dec 13
PRE 14A
Preliminary proxy
6 Dec 13
Other
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
26 Apr 17
CORRESP
Correspondence with SEC
29 Mar 17
UPLOAD
Letter from SEC
16 Mar 17
CORRESP
Correspondence with SEC
7 Mar 17
UPLOAD
Letter from SEC
23 Feb 17
UPLOAD
Letter from SEC
11 Mar 16
CORRESP
Correspondence with SEC
19 Feb 16
UPLOAD
Letter from SEC
9 Feb 16
CT ORDER
Confidential treatment order
11 Jan 16
Ownership
SC 13G/A
Lannett Co Inc
10 Sep 19
SC 13G/A
Lannett Co Inc
9 Aug 19
SC 13G/A
Lannett Co Inc
9 Aug 19
SC 13G/A
Lannett Co Inc
10 Jul 19
SC 13G/A
Lannett Co Inc
10 Jun 19
SC 13G/A
Lannett Co Inc
10 May 19
SC 13G/A
Lannett Co Inc
5 Apr 19
SC 13G/A
Lannett Co Inc
11 Mar 19
SC 13G/A
Lannett Co Inc
25 Feb 19
SC 13G
Lannett Co Inc
13 Feb 19